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Abstract
Background—Sleep apnea is a common condition and has a direct impact on cognitive function.
The impact of sleep apnea, and its interplay with other established risk factors on the risk of
incident dementia, warrants exploration.
Objectives—To investigate the association between baseline sleep apnea and risk of incident
dementia in the Prevention of Alzheimer’s Disease with Vitamin E and Selenium (PREADViSE)
study and explore whether the association depends on APOE ε4 allele status.
Design—Secondary analysis based on data collected during PREADViSE.
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Setting—Participants were assessed at 128 local clinical study sites during the clinical trial phase
and later were followed by telephone from a centralized location.
Participants—7,547 male subjects were enrolled in PREADViSE.
Measurements—Participants were interviewed at baseline for sleep apnea. The Memory
Impairment Screen (MIS) was administered to each participant annually. Subjects who failed to
this initial screen were tested with secondary screening tests. Additional measures collected
include medical history, medication use, and the AD8 dementia screening instrument.
Results—The effect of self-reported sleep apnea on dementia risk depended on APOE ε4 status.
When the allele was absent, baseline self-reported sleep apnea was associated with a 66% higher
risk of developing dementia (95% CI 2%–170%), while self-reported sleep apnea conferred no
additional risk for participants with an ε4 allele.

Author Manuscript

Conclusion—Sleep apnea may increase risk of dementia in the absence of APOE ε4. This may
help inform prevention strategies for dementia or AD in older men with sleep apnea.
Registration—PREADViSE is registered at ClinicalTrials.gov: NCT00040378.
Keywords
self-reported sleep apnea; dementia; APOE

INTRODUCTION

Author Manuscript

Dementia is a syndrome that affects memory, thinking, behavior and ability to perform
everyday activities. In 2010, Wimo and colleagues estimated global dementia prevalence at
35.6 million people, and this number is expected to double by 2030 and more than triple by
2050. Moreover, estimated annual costs of dementia reached $604 billion (U.S. dollars) in
2010[1, 2]. With rising prevalence, these costs are expected to increase by 85% by 2030,
which would make dementia the most expensive chronic disease associated with aging.
Sleep apnea is a common age-associated type of sleep disordered breathing (SDB), with
clinical symptoms including loud snoring, breathing pauses such as choking or gasping
during sleep, morning headaches, insomnia, and daytime sleepiness [3–5]. Sleep apnea and
risks associated with it, such as obesity, are becoming an increasingly important public
health issues for adults [3, 4, 6–9]. The prevalence of sleep apnea varies by age and sex and
is more common in older adults and men [4, 10, 11]. It is estimated to be present in 20 to
50% of older adults [4]. For people aged 50–70 years old, 17% of men and 9% of women
are estimated to have moderate-to-severe SDB [12].

Author Manuscript

Sleep apnea is associated with cognitive impairment and dementia in older populations [13,
14]; however, the relationship between pre-existing sleep apnea and incident cognitive
impairment and dementia remains poorly characterized. Many existing studies are limited by
cross-sectional study designs, small sample size, or short follow-up time [15, 16]. Three
cross-sectional studies in populations aged over 65 years found no association between the
apnea-hypopnea index and cognitive function [17–19]. By contrast, in a prospective study of
298 women, Yaffe et al. [20] found that SDB was associated with a 71% increased risk of
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developing mild cognitive impairment (MCI) or dementia over 5 years after adjusting for
age, race, body mass index, education level, smoking status, presence of diabetes, and
hypertension. A retrospective population-based study also showed increased risk of
developing dementia for a Taiwanese population aged over 40 years who participated in a
national health insurance program [21]. Sleep apnea patients had a 170% increase in
dementia risk compared with patients without sleep apnea after adjustment for age, sex,
hypertension, diabetes, stroke, and hyperlipidemia during the 5-year follow-up period [21].
Finally, an eight-year study of older adults found only small effects of SDB on decline in
attention, but not memory, once other medical comorbidities were included in their statistical
models[14].

Author Manuscript

However, these cohort studies were unable to consider the effect of the genetic risk factor,
APOE [22], on risk of dementia. Since APOE is a major unmodifiable risk factor for
dementia due to Alzheimer’s disease (AD), the most common form of dementia, it is
important to understand whether sleep apnea or SDB might differentially influence the risk
of dementia based on the status of APOE genotype. To our knowledge, only three studies
have explored this association. O’Hara et al. conducted a small cross-sectional study (n=36)
and found that SDB was only associated with impairment of verbal memory in APOE ε4
allele carriers [23], while Osorio and colleagues (n=95) found only a trend toward lower
CSF Aβ-42 levels in APOE ε4 positive normal older adults with SDB [6]. A second study
by Osorio and colleagues based on the Alzheimer’s disease Neuroimaging Initiative
database (n=2,285) found that SDB was associated with younger age at onset of MCI, and
this was not affected by APOE ε4 carrier status [24]. Additional studies are needed to
investigate this topic.
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Using Prevention of Alzheimer’s Disease (AD) by Vitamin E and Selenium (PREADViSE)
trial data, which comprises 7,547 male subjects who were free from dementia at baseline, we
sought to investigate two research hypotheses: (1) older men with self-reported sleep apnea
prior to cognitive impairment have an increased risk of dementia, and (2) older men with
self-reported sleep apnea have different risks for dementia based on APOE allele status.

METHODS
Study population and data sources

Author Manuscript

We conducted a secondary analysis of sleep apnea and incident dementia among 7,547
subjects enrolled in the PREADViSE trial [25]. The PREADViSE trial is an ancillary study
to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (a large prostate cancer
prevention randomized controlled trial (RCT)) [26] and was designed to evaluate the
effectiveness of antioxidant supplements vitamin E and selenium in preventing incident AD
and other forms of dementia. PREADViSE investigators were blind to SELECT treatment
assignment as of this writing, and so the effects of the antioxidant supplements will not be
considered further here. During the recruiting period from 2002 to 2009, PREADViSE
enrolled 7,547 non-demented male participants age 62 years and older (age 60 if African
American) from 128 participating SELECT clinical sites in the US, Canada, and Puerto
Rico. The eligibility criteria for participating in PREADViSE included active SELECT
enrollment at a participating site and absence of dementia and other active neurologic
J Am Geriatr Soc. Author manuscript; available in PMC 2017 December 01.
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conditions that affect cognition such as major psychiatric disorder, including depression. All
7,547 participants are included in the current study; no further inclusion and/or exclusion
criteria were applied for this secondary analysis.

Author Manuscript

The study supplements in SELECT were discontinued by its Data Safety Monitoring
Committee in 2008 following a futility analysis [27]; PREADViSE and SELECT then
continued as observational exposure cohort studies. The details of this evolution for
PREADViSE can be found in Kryscio et al. [28]. All participants were asked to continue in
the exposure study, and 4,271 of 7,547 original PREADViSE volunteers consented to
participation (Figure 1). PREADViSE was approved by the University of Kentucky
Institutional Review Board (IRB) as well as the IRBs at each SELECT study site. Each
participant provided written informed consent. During the RCT phase, SELECT sites used a
web-based data collection system to submit data directly to the Cancer Research and
Biostatistics Group, who managed the data for SELECT. SELECT provided monthly
snapshots of PREADViSE data elements to PREADViSE via a secure file transfer protocol
(ftp) site. During the observational phase, data were collected at a single site, the University
of Kentucky.
Case Ascertainment

Author Manuscript

The Memory Impairment Screen (MIS) [29] was used as the primary screening instrument
for dementia in both the RCT and observational portions of PREADViSE. The MIS was
given annually. If participants failed the MIS (that is, the participant scored 5 or less out of 8
on either the immediate or delayed recall portion of the MIS), a second tier screen was
administered. An expanded Consortium to Establish a Registry in AD battery (CERAD-e)
[30] was used during the RCT period and the modified Telephone Interview for Cognitive
Status (TICS-m) [31], was used during the observational study. Both the CERAD-e and the
TICS-m assessed participants’ global cognitive function. Failure on the secondary screen (T
score ≤ 35 on CERAD-e battery or total score ≤ 35 on TICS-m) would lead to a
recommendation for a clinic visit with their local physician. Records from the clinic visit
were reviewed by 3–5 expert clinicians, including two neurologists and at least one
neuropsychologist, for a consensus diagnosis. In cases where the neurologists disagreed in
their diagnoses, the study PI made the final determination. Annual screenings were
completed in May 2014, and a small number of participants were followed for medical
records through August 2015.
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The incident dementia cases were identified through two methods. First, as described above,
a medical records-based consensus diagnosis was used. Date of diagnosis was assigned as
the date of the failed screen. Second, because many participants were reluctant to obtain
medical workups for their memory, additional longitudinal measures including the AD8
Dementia Screening Interview [32], self-reported medical history, self-reported diagnosis of
dementia, use of memory enhancing prescription drug, and cognitive scores including the
MIS, CERAD-e T Score, NYU Paragraph Delayed Recall, and TICS-m were used to
identify cases. The diagnostic criteria for the second method were AD8 total of ≥ 1 (at any
time during follow-up) to indicate functional impairment [32] plus one of the following: a
self-reported diagnosis of dementia, use of a memory enhancing prescription drug
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(donepezil, rivastigmine, galantamine, or memantine), or cognitive score below cutoffs for
intact cognition on any test (for example: 1.5 SDs below expected performance based on age
and education normative data[3]. The date of diagnosis was assigned to the earliest event.
Sleep Apnea
All participants were asked during the baseline PREADViSE interview whether they had
ever been treated for sleep apnea. Responses were recorded as “yes” or “no.”
APOE genotype

Author Manuscript

APOE ε4 positivity is a major risk factor for AD-type dementia [4]. APOE genotype was
obtained for 7,180 participants (ε2/2: 51 (0.71%); ε2/3: 879 (12.24%); ε2/4: 190 (2.65%);
ε3/3: 4,320 (60.17%); ε3/4: 1,599(22.17%); ε4/4: 141(1.96%)). The genotypes were
converted to a dummy indicator for at least one ε4 allele, where the presence of at least one
ε4 allele was considered a carrier. SAS 9.4® procedure PROC MI was used to impute
missing values for the indicator variable (367/7547 (5%)) based on family history of
dementia. Four imputed data sets were generated; participants with two or more positive
imputations for APOE ε4 were coded as APOE ε4 positive.
Other Covariates

Author Manuscript

Other data collected included age at baseline, race, body mass index (BMI), years of
education, as well as self-reported indicators of cardiovascular disease (i.e., diabetes,
hypertension, and smoking). These are recognized risk factors for dementia [5]. History of
significant cognitive or motor impairment due to stroke was a PREADViSE exclusion
criterion so baseline prevalence of stroke in the cohort is extremely low (0.6%), thus stroke
was not considered further.
Statistical analysis

Author Manuscript

Chi-square and t test statistics were used to examine differences in categorical and
continuous variables between sleep apnea groups. The log-rank test was used to assess
differences in crude cumulative risk of dementia between sleep apnea groups. A series of
Cox proportional hazards regression models with self-reported sleep apnea as the
independent variable, survival time to diagnosis of dementia as the dependent variable, and
the covariates listed above were applied to simple and multivariable survival analyses, where
follow-up time was defined as the period in years between date of PREADViSE study entry
and date of dementia diagnosis or, in the absence of dementia, date of last assessment. The
multivariable model included main effects for baseline age, years of education, body mass
index (BMI), race (black vs. non-black), APOE (presence of APOE ε4 or absence of APOE
ε4), smoking (yes vs. no), self-reported baseline status of diabetes and hypertension (coded
present or absent). Covariates were fixed at baseline. The proportional hazards assumption
was tested by checking the interaction between time and each covariate. Interaction terms
between history of sleep apnea and each covariate in the model were also tested. None of the
interactions were significant. Given the sufficient sample size in each APOE group (n =
2029 and 5518 in APOE ε4 positive group and negative group, respectively), we also
evaluated the effect of sleep apnea on risk of dementia stratified by APOE ε4 to evaluate for
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effect modification between sleep apnea and APOE. All data were analyzed by using SAS
9.4® (SAS Institute, Inc., Cary, NC), and 0.05 was set as the significance level.

RESULTS
Demographic attributes of participants from PREADViSE are shown in Table 1. Briefly,
7.3% (552/7547) of the men reported history of sleep apnea at baseline. The absolute
difference in baseline age between men with and without sleep apnea was significant but not
large (Table 1). Men with history of sleep apnea at baseline were significantly more likely to
be of black race (p = 0.02), smokers (p<0.001), have higher BMI (p < 0.001), and were more
likely to report hypertension (p<0.001) and diabetes (p<0.001). No significant differences
were observed in educational attainment or proportion of APOE ε4 carriers.
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A total of 310 (4.1%) men were diagnosed with dementia (4.0% for men without sleep
apnea, 5.1% for men with history of sleep apnea, respectively; p = 0.24). The cumulative
incidence accounting for censoring during follow-up was estimated to be 9.3% in the nonsleep apnea group and 24.4% in sleep apnea group (Figure 2). However, this difference was
not significant due to the relatively small number of dementia cases in the sleep apnea group
(p = 0.14 by the log-rank test).
Table 2 displays hazard ratios for dementia diagnosis from adjusted Cox models. History of
sleep apnea was borderline significant in the adjusted model (HR = 1.44; 95% CI 0.96 –
2.17, p = 0.08). In this adjusted analysis, men with sleep apnea were more likely to develop
dementia compared to men without sleep apnea. Black race, APOE ε4 carrier status, and
baseline age were significantly associated with dementia risk. Interaction terms between
sleep apnea and each covariate in the model were tested, but none were significant.

Author Manuscript

Stratified analyses by status of APOE ε4 were conducted, and results are shown in Table 2.
For men without an APOE ε4 allele, history of sleep apnea conferred a 66% (95% CI 2%–
170%) higher risk of developing dementia (Figure 3a). Sleep apnea had no effect when the
APOE ε4 allele was present (Figure 3b).

DISCUSSION

Author Manuscript

In this study, self-reported baseline history of sleep apnea was borderline significantly
associated with risk of dementia after adjustment for confounding (p = 0.08). Stratified
analysis by APOE ε4 carrier status showed that baseline history of sleep apnea was
associated with significantly increased risk of dementia in non-carriers. For the latter, selfreported sleep apnea was estimated to confer a 66% higher risk to develop dementia (p =
0.0423). Age, race, and APOE were significantly associated with the risk of dementia in the
multivariable Cox model. We did not find any significant associations for years of education,
smoking, BMI, presence of diabetes, or hypertension in either the primary or the stratified
analyses with the exception of smoking, which significantly increased risk for APOE ε4
carriers. None of the two-way interactions between self-reported sleep apnea and other
covariates were significant, including APOE ε4, which was likely due to a lack of sufficient
statistical power to detect the interaction despite the difference in the stratified analysis.
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There are very few prospective studies that have investigated the association between sleep
apnea and risk of dementia in an older adult male population. We did not find clear evidence
that history of sleep apnea, prior to cognitive impairment, was associated with dementia in
men overall, which is similar to the findings reported in Osorio’s recent study [24] and
several other cross-sectional studies [17–19]. However, our results did show that sleep apnea
is significantly associated with dementia risk for men who were APOE ε4 allele noncarriers. This is contradictory to the finding of one small cross-sectional study [23], which
found that the association existed only for APOE ε4 allele carriers, but similar to Osorio et
al.’s study [6], in which CSF amyloid beta 42 and tau were not associated with sleep apnea
in APOE ε4 allele carriers but were associated in noncarriers [6]. Such discrepancies are
likely the result of differences in exposure and outcome assessment, residual confounding,
covariates adjusted for, sample size, study population, or study design.
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Similar to other studies [6, 23], our results indicated an interaction effect of sleep apnea and
APOE ε4 on the risk developing dementia. This is particularly important considering both
the high prevalence of sleep apnea in older populations [4] and the high percentage of APOE
ε4 non-carriers in the population (~75%) [33]. So far, several prevention trials [14, 33] have
been completed with null or inconclusive results. Since the APOE ε4 allele is a well-known
and non-modifiable risk factor for AD, the findings of this study may help inform prevention
strategies for dementia or AD in older men with sleep apnea. Osorio and colleagues [32]
suggest that treatment with continuous positive airway pressure (CPAP) may delay onset of
MCI. It is of course important that all patients with sleep apnea are diagnosed and treated,
but diagnosis and treatment of sleep apnea may be especially helpful in preventing or
delaying incident cognitive impairment in the aging male population with SDB who are
APOE ε4 non-carriers.
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Possible mechanisms that could explain the association of sleep apnea with risk of incident
cognitive decline and dementia include direct effects on cerebral oxygenation and the
selective vulnerability of hippocampal neurons to hypoxia, or perhaps augmentation of
vascular contributions that have been strongly linked to the development of MCI, AD, and
other forms of dementia [20, 35]. Chronic hypoxia has been linked to hippocampal injury
that may lower the threshold for the development and or spread of tau-associated
neurodegeneration [36]. The development of sleep apnea has also been shown to exacerbate
cardiovascular risk factors such as hypertension, and to be strongly associated with obesity,
insulin resistance, hyperlipidemia, and the development of the metabolic syndrome [29, 37].
Thus, there may be many ways that sleep apnea contributes to derangements in metabolic
pathways that have been strongly associated with increased risk of incident MCI or dementia
in the aging population. Indeed, the present data demonstrate increased prevalence of
hypertension and diabetes in those with sleep apnea, although the association with APOE
status appeared independent of such conditions in the adjusted analysis, suggesting that
other mechanistic factors may be important to consider.
Another possible mechanism for the association of sleep apnea and risk of dementia is that
sleep may help regulate brain amyloid-β levels [38, 39]. A recent study in transgenic mice
demonstrated that levels of brain amyloid-β increased when both normal and AD mouse
models were awake and then decreased during sleep [40]. This diurnal variation in amyloid
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production could be dramatically altered in persons with sleep apnea or other sleep
disturbances [41]. A small study [42] of community-based older adults was able to
demonstrate that shorter sleep duration was significantly associated with increased amyloidβ levels. There is also some evidence that APOE might play a role in degradation of
amyloid-β [3]. APOE ε4 carriers show lower concentration of amyloid-β in the
cerebrospinal fluid, indicating increased amyloid-β deposition in the brain [6]. In the
presence of APOE ε4, any increase in brain amyloid-β associated with sleep apnea may be
overwhelmed by that due to APOE ε4 alone. However, it remains unclear why amyloid-β is
affected by the sleep cycle or how it depends on the APOE genotype. [44]
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This study has some limitations. Not all participants who failed the memory screenings were
willing to visit their doctors for a memory work-up, so case ascertainment may be less
accurate due to lack of medical records. However, application of the secondary dementia
criteria (positive AD8 screen, self-reported diagnosis, use of memory enhancing drug, and
poor cognitive scores) demonstrated good agreement in the cases where the diagnosis was
known (data not shown). Because only a subset of subjects participated in both the RCT as
well as the exposure phases of PREADViSE, some cases may have been missed among the
subjects who did not participate in the exposure study. Our data show there were 46.2%
participants who had sleep apnea at baseline and did not continue to participate in the study,
while 50.1% subjects without sleep apnea in the baseline cohort did not continue. Therefore,
the loss of cases would be estimated to be the same for the subjects with and without sleep
apnea. We measured sleep apnea with self-report, similar to Osorio et al. [24]. Due to the
phrasing of the questionnaire, undiagnosed and or untreated sleep apnea subjects may have
been missed [45]. However, because ascertainment of sleep apnea occurred at baseline, it is
independent of dementia ascertainment. Therefore, if there is misclassification of sleep
apnea exposure, it is non-differential misclassification, and will bias the association toward
the null [44], that is, to lessen the degree of association. Thus, our analysis likely
underestimates the effect of sleep apnea on dementia risk. Since the study population is all
older men, the findings from this study cannot be generalized to older women. However, the
current findings align quite well with those reported by Yaffe and colleagues who showed an
increased risk for dementia with SDB in older women [20]. Strengths for the study include
the large sample and long follow-up. We were also able to consider most well established
risk factors for dementia including demographic, genetic, and medical characteristics,
including cardiovascular risk factors.

CONCLUSION
Author Manuscript

Our study provides evidence that in the absence of APOE ε4, sleep apnea may increase the
risk of dementia in older men. This may occur through the disruption of brain amyloid-β
regulation that occurs during the sleep cycle, or through cerebrovascular damage, although
the exact mechanism remains unclear [43]. Considering the limited number of publications
in this area and the inconsistent findings, replication studies with objective measures of sleep
apnea, long follow-up, and rigorous methods to diagnose dementia are needed to support
this finding conclusively.
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From the standpoint of clinical practice, many primary care physicians are unaware of their
patients’ genetic status and APOE genotype in particular. However, with adequate screening
of SDB symptoms along with other risk factors (e.g., age, ethnicity) our findings along with
those of O’Hara et al. [23] and Yaffe et al. [20] we would advise the clinician to work with
all their patients to address sleep apnea problems as soon as possible given the association
with future cognitive dysfunction.
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Participant flow diagram for PREADViSE
*PREADViSE was an ancillary study to SELECT; enrollment was from May 2002 through
November 2009 (N=7,547). PREADViSE participants were invited to participate in
centralized follow-up (PREADViSE CFU) following the closure of SELECT due to a futility
analysis. Some SELECT sites decided not to offer their participants the opportunity to
participate in CFU; these participants are listed above as being ineligible. PREADViSE CFU
continued to follow participants from August 2010 – August 2015.
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Figure 2.

Probability of dementia by history of sleep apnea (SDB) at baseline. Solid line indicates
sleep apnea, dashed line indicates no sleep apnea. Time axis ends at 10 years for consistency
among figures.
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Figure 3.
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Figure 3a & 3b. Probability of dementia at baseline by history of sleep apnea (SDB) status
after adjusting other covariates in APOE ε4 non-carriers (a) and carriers (b). These
hypothetical participants are white, age 68 at baseline, smoke, have 15 years of education
and baseline BMI 28.5 kg/m2, and comorbidities including presence of hypertension and
diabetes. Solid line indicates sleep apnea, dashed line indicates no sleep apnea. Time axis
ends at 10 years for consistency among figures.
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General Characteristics of the Study Population in PREADViSE
Characteristic

All Subjects (N=7,547)

No Sleep Apnea (n=6,995)

Sleep Apnea (n=552)

P value

Baseline agea, y, mean±SD

67.5±5.3

67.6±5.3

66.6±4.5

< 0.001

Educationc, y, mean±SD

15.0±2.7

14.9±2.7

15.1±2.6

NSb

Black race

756 (10.0)

685 (9.8)

71 (12.9)

0.02

Baseline smokingd

4260 (56.6)

3916 (56.1)

344 (62.4)

0.004

APOE-ε4 (≥1 ε4)

2,029 (26.9)

1876 (26.8)

153 (27.7)

NSb

Baseline hypertension

2,998 (39.7)

2703 (38.6)

295 (53.4)

<0.001

858 (11.4)

762 (10.9)

96 (17.4)

<0.001

Baseline BMIef, kg/m2, mean±SD

28.5±4.4

28.2±4.2

31.6±5.3

<0.001

Follow-up time, y, mean±SD

5.7±2.8

5.7±2.8

5.5±2.8

NSb

Baseline diabetes

Author Manuscript

a

N = 7546 for age;

b

NS: Not significant;

c

N = 7,512 for education;

d

N = 7528 for smoking;

e

BMI: Body Mass Index;

f

N = 7515 for BMI.

Note: Results presented are mean±SD or N (%). All PREADViSE participants are male.
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Association between History of Sleep Apnea and Risk of Dementia based on Adjusted Cox Model and
Stratified Analysis by APOE ε4 Status
Stratified Analysis
Adjusted HRb (95% CI)

Author Manuscript

a

Adjusted HRb (95% CI)

APOE ε4 carriers (N = 2,029)

APOE ε4 non-carriers

Sleep apnea

1.44 (0.96–2.17)

1.13 (0.54–2.37)

1.66 (1.02–2.70)

Baseline age, 1 year

1.11 (1.09–1.13)

1.14 (1.10–1.17)

1.09 (1.07–1.12)

Education, 1 year

0.98(0.94–1.02)

1.01 (0.94–1.08)

0.95 (0.91–1.01)

Black race

1.73 (1.19–2.52)

1.71 (0.97–3.03)

1.72 (1.05–2.82)

Baseline smoking

1.20 (0.95–1.51)

1.55 (1.06–2.26)

1.03 (0.77–1.38)

APOE ε4 carrier

1.99 (1.58–2.50)

--

--

Baseline HTNc

0.92 (0.73–1.17)

0.83 (0.56–1.21)

0.98 (0.72–1.33)

Baseline diabetes

1.10 (0.78–1.57)

0.83 (0.43–1.58)

1.29 (0.85–1.97)

BMId,, 1 kg/m2

0.99 (0.97–1.02)

1.00 (0.95–1.04)

0.99 (0.96–1.03)

All variables listed in the table were included in the adjusted models.

b

HR: Hazard Ratio;

c

HTN = hypertension;

d

BMI = body mass index.
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